The assessment of growth in children with kidney disease includes measurements of stature, nutritional status, skeletal maturity, and sexual development. The purposes of these assessments in general are described in the preceding paper (Roche, this issue). For the child with kidney disease, the number of variables affecting growth make it difficult to project adult stature. When a specific variable is dominant, data is accumulating that make this projection possible. Elsewhere (Potter and Greifer;
Travis et al, this issue) is summarized experience in children with various types of renal insufficiency and in children after renal transplantation. Growth rate can be improved but not sufficiently so that stature and development are normal. By contrast, children with uncomplicated renal tubular acidosis (RTA) when treated adequately from an early age may exhibit catch-up growth and attain normal stature (McSherry, this issue).
Growth assessment in the individual child with kidney disease is helpful to physician and patient in understanding the course of his disease, the effect of therapy, and in gaining some projection of growth potential. Serial growth assessment of a group of children is helpful toward defining the variables of disease most affecting growth. From such data the natural history of disease can be defined in relation to its effect upon ultimate stature and development. Response of growth to therapy to evaluate the potential efficacy of therapy is a third reason for assessing growth.
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Stature is the index of growth of most concern to children. How tall they are, how fast they are growing, and how tall they are going to be are the important questions. Measuring stature serially is the first requisite. Nutritional status, skeletal maturation, and sexual development, however, all influence statural growth and remaining growth potential.
These variables also are important in themselves in evaluating the course of the disease and in planning therapy.
Judging from past experience, there is a need to develop guidelines for presenting data on growth assessment of children with kidney disease, The recommendations in this report are presented as a step towards fulfilling that need. Drawing from the previous paper (Roche, this issue), we recommend the following measurements to be made at intervals 3) Body weight. Weight should be measured in the fasting or postabsorptive state, or at a standard time of day. In dialyzed patients, weight should be measured immediately after the dialysis session. Except for the first month after start of dialysis, mean values of several postdialysis weights should be reported. For both measurements of stature and weight, only very light clothing should be worn.
4) Skinfold thickness. Skinfold thickness should be measured at the triceps and subscapular sites bilaterally using calibrated calipers. At the triceps site, skinfold thickness should be taken at the level of the midpoint between marks plotted over the left acromion and olecranon in the midline of the posterior aspect of the arm, when this is hanging relaxed. The subscapular site is just inferior to the angle of the scapula. The site of measurements and the presence of any anatomical abnormalities, such as an arteriovenous shunt or fistula, which might influence the value obtained, should be clearly indicated. The measurement can be used to estimate body fat [4, 51. 5) Upper arm circumference. Upper arm circumference is measured bilaterally to obtain an index of muscle mass. The measurement is made to the nearest millimeter at the same level as for the measurement of the triceps skinfold thickness using a tape that does not stretch. The expanded end tape is recommended (see Roche, this issue). The arm circumference plus the triceps skinfold thickness can be used to calculate the cross-sectional area of fat and of muscle plus bone [4, 5] . 6) Head circumference. Head circumference is measured up to the age of 3 yr with the tape mentioned under no. 5. Children with kidney disease characteristically have normal head growth.
7) Radiography. Radiographs should be taken at 6-month intervals to obtain data about skeletal maturity and skeletal status including osteodystrophy. These radiographs should be on left handwrist and left knee. a) Skeletal maturit. Skeletal maturity assessments are needed because of the relationship of skeletal maturation to other aspects of development and to a child's potential for growth in stature. Recently published methods for the assessment of the hand-wrist [6, 7] and the knee [81 are recommended rather than the Greulich-Pyle Atlas [9] for the handwrist. The method used should be recorded. These assessments should be made by an independent observer to reduce bias and errors: consultations or special arrangements can be made with those who developed these assessments. b) Skeletal status. Radiographs should be screened for rickets, signs of secondary hyperparathyroidism (e.g., subperiosteal resorption) and osteosclerosis. The amount of bone mineral present should be estimated from the measured thickness of the cortex of the second metacarpal or other bones and/or by absorptiometry. In the future, computerized tomography may be used to estimate bone All measurements should be taken at intervals of 6 months from the first observation of a child with a progressive kidney disorder when stature is more than 2 SD below the mean for age or when growth velocity during a year is below the 5th percentile. In end-stage renal disease patients, the measurements should be obtained at the time of the first dialysis or immediately before transplantation, respectively, and at 6-month intervals thereafter, as well as at each change of the mode of treatment (peritoneal or hemodialysis, hospital or home dialysis, at each transplantation, etc.). The European Dialysis and Transplant Association proposed additional measurements at the end of each calendar year [1] .
In children with renal insufficiency and in children after transplantation, the data on growth and development should be supplemented by concomitant measurements of kidney function and of nutritional status [13] . In dialyzed patients, the frequency and duration as well as other clinical details of the dialysis procedure should be noted. In patients receiving steroid therapy, the total dose of corticosteroid given per month should be recorded.
Potter et a!
The methods used should be described, and data obtained should be entered on flow sheets and graphs systematically for easy data retrieval.
Utilization of data from an individual child Sequential data on stature and weight, recorded as discussed above, should be plotted on appropriate charts against chronologic age and kept in the patient's record. This documents the child's progress in relation to his peers, which is important information to the child, and allows the relation of weight to stature to be examined. The child's stature in relation to parental stature can also be assessed using appropriate charts (see Roche, this issue). Sequential measurements of stature should be plotted against estimates of skeletal maturity recorded as bone age or maturity scores 6-8I. Standard stature for age charts can be used for this purpose substituting bone age for chronological age. The mean bone age and chronological age will correspond, but the percentiles or standard deviations for stature around the mean will not necessarily be the same for bone age as for chronologic age. This plot is particularly important in evaluating growth potential because of the relationship between growth potential and skeletal maturation and the frequency of retardation of skeletal maturation in children with chronic renal failure.
Increments in stature over a 1-yr period can also be plotted against the age of the child (growth velocity) l4]. When the increments in stature are related to an interval in skeletal maturation and plotted against the bone age rather than chronologic age, the data can be evaluated more accurately in terms of the growth potential of the child. Errors inherent in determining growth velocity in this way are a composite of the error of the stature increments (small) and the assessment of bone age (larger), and consequently the sum of errors is larger than the error involved in the construction of the conventional growth velocity chart which related increments in stature to chronologic age. Therefore, the interval between assessment should be sufficient to minimize the error of measurement of bone age. Estimates of growth velocity are variable from period to period in an individual child (see Roche, this issue). The technique of curve-fitting described by Roche promises to improve the usefulness of this method. Growth velocity charts are also useful in judging differences between groups of children, and this is discussed below.
Growth rate in the first two years of life is very rapid, so that growth-retarding influences in this penod are particularly serious [15] . Growth velocity (in centimeters per year) from 3 yr of age to puberty is relatively constant, as is the standard deviation of growth velocity for that period. With the onset of puberty and the pubertal growth spurt, variability again makes it difficult to evaluate change. Comparing growth velocity with skeletal maturity and sexual maturation removes some of the variability. Growth retardation associated with comparable retardation of skeletal maturity has less effect on growth potential than growth retardation when skeletal maturation proceeds. These factors are important considerations in evaluating growth of the individual child or growth data from a group of children.
Utilization of data from group data: Single variable
Group data are used to define the natural history of a disease upon growth including the impact of specific complications or therapies. Describing the natural history of a congenital disease upon growth has the advantage in that the disease is present at birth.
Data from children with congenital disease and growth retardation by 3 yr of age can be expressed as standard deviation scores, and the average of these scores can be used to express the magnitude of growth impairment for the group. Where the data are cross sectional, each child should be entered only once. The standard deviation scores can be treated statistically as any set of numbers.
The more conventional method for expressing data from a group is the presentation of individual data on a standard growth chart or growth velocity chart that conveys a visual impression of growth performance. Growth performance of individuals in the group can be expressed over a period of time by this method, but it is not suitable for statistical treatment. Growth or growth velocity for a group can also be expressed in relation to bone age to indicate qualitatively the remaining growth potential. Data expressed by this method, however, cannot be treated statistically.
When two groups of children are to be compared in terms of growth impairment, the age and skeletal maturity scores should be between ages 3 and II. For this interval, it is ideal to treat boys and girls separately, but if like numbers are in each group and the individuals are prepubertal, they may be combined. The simplest method for comparing two groups with statistical methods is the expression of stature as standard deviation score. Each child should appear only once in a group. When stature is expressed as a standard deviation score, with bone age rather than chronologic age as the reference, it should be noted that the standard deviation for the normal population refers to chronologic age and some error is introduced. This error, however, may not be large especially when comparing groups of children. Data providing standard deviations of stature versus bone age for normal children would be very useful in eliminating this error.
When the effect of therapy is being evaluated, the comparison may be between a control and test group for a period time, or between a control and treatment period in the same patients. The sequence in the serial study should be random. In either case, the period of observation need be only as long as that required either to show no effect in a period when a response can be expected (negative result) or long enough for therapy to change stature when compared with controls (positive result). Seasonal effects can be ignored when entry into study is random with respect to time, and seasonal effects are therefore randomly distributed. When the result is positive, it usually will be necessary to conduct a second study of longer duration and to compare the effect of therapy upon skeletal maturity as well as growth velocity.
Using standard deviation scores is preferred to expressing growth as centimeters per year or as 100% normal, because "normal" growth velocity for growth-retarded children is not known. Standard deviation scores of stature also are preferred to expressing growth velocity in relation to standard deviation of normal growth velocity although for purposes of comparing growth velocity between two groups, this method may be useful.
When growth velocity of two groups of children are expressed in relation to a change in bone age, the data are less precise because there is a relatively large inaccuracy in assessing bone age.
When comparisons of weight are made, the data may be expressed in relation to height graphically, or they may be expressed as a percent of weight appropriate for height [16] . When expressed in this latter mode, statistical comparison is possible. Errors of interpretation of weight occur when edema is present (see Holliday and Chantler, this issue).
When skinfold thickness and arm circumference measurements are compared between groups or serially in the same group, it is possible to test for significance of difference. When two groups are being compared, however, it is important that they have the same age and sex distribution; and when serial increments are obtained, it is desirable that the control and test periods be randomly assigned first place in the sequence.
Summary
The serial measurement of stature, weight, skinfold thickness, mean arm circumference, skeletal maturity, and where appropriate, stage of sexual development are recommended as suitable indices for assessing growth in children with kidney disease. Methods of expressing the data for evaluating the individual child are generally used methods.
Emphasis is given to relating stature to bone age in evaluating growth potential. Methods for comparing growth rates in groups of children are less well-developed. Using standard deviation scores is recommended for comparing stature in two groups of children or in the same child observed at the end of two different regimens. Weight using ideal weight-for-height as reference from a group of children can be treated statistically. Data of skinfold thickness and arm circumference from two groups can be handled statistically only when the groups are comparable in age and sex.
